In the previous issue of Critical Care, Pradelli and colleagues [1] presented a new meta-analysis of parenterally administered marine omega-3 fatty acids (also known as 'fi sh oil') in non-intensive care unit (non-ICU) (elective surgical) and ICU patients, with results considered separately and in combination. An earlier metaanalysis restricted to patients undergoing elective major abdominal surgery concluded that parenteral fi sh oil signifi cantly reduces infection rate (odds ratio: 0.56; P = 0.04), length of ICU stay (stay 1.92 days shorter; P = 0.004), and length of hospital stay (stay 2.98 days shorter; P = 0.0005) [2] . Pradelli and colleagues [1] extend this earlier analysis by considering a broader range of patients, by including papers published between 1997 and 2011, and by reporting on fi ndings for a range of laboratory parameters in addition to the clinical outcomes. Ultimately, 23 studies were included (13 of patients admitted to the ICU and 10 of patients undergoing major abdominal surgery and not admitted to the ICU), involving a total of 1,502 patients. Of the studies involving the ICU, nine were of patients who had undergone major abdominal surgery. Th e other four studies involved patients with sepsis [3], critical illness [4], acute respiratory distress syndrome [5] , or severe acute pancreatitis [6] . Th ere was no eff ect of parenteral fi sh oil on mortality, either overall (n = 10 studies) or in the two separate patient groups. Furthermore, there was no eff ect on bleeding-related outcomes, although these were reported in relatively few studies. However, the analysis confi rmed that, for the non-ICU and ICU patients combined, parenteral fi sh oil signifi cantly reduces infection rate (n = 11 studies published from 1997 to 2011; risk ratio: 0.61; P = 0.002), length of ICU stay (n = 8 studies published from 1997 to 2010; stay 1.92 days shorter; P = 0.005), and length of hospital stay (n = 14 studies published from 1997 to 2011; stay 3.29 days shorter; P = 0.0005) [2] . Th e similarity of the fi ndings to those of the earlier, apparently more restricted, meta-analysis by Chen and colleagues [2] is striking. Th e reasons for this similarity are that there is signifi cant overlap of papers considered in the two analyses and that, although the study by Chen and colleagues was restricted to patients undergoing abdominal surgery, those authors combined fi ndings for non-ICU and ICU patients. In the new metaanalysis, parenteral fi sh oil signifi cantly reduced infection rate in non-ICU but not in ICU patients, although the sizes of the eff ect were fairly similar in the two groups (risk ratios were 0.53 in non-ICU patients and 0.71 in ICU patients). In contrast, the eff ects on hospital length of stay were signifi cant in both groups of patients (−1.86 days in non-ICU patients and −5.17 days in ICU patients). Lung oxygenation index was reported in two studies in septic ICU patients [3, 6] and overall was found to be signifi cantly improved with parenteral fi sh oil.
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Th e fi ndings of this meta-analysis are highly encouraging as far as patients in the ICU are concerned. Th ere are two possible explanations for the lack of a signifi cant eff ect on infection rate in ICU patients despite signifi cant reductions in ICU and hospital stays. Th e fi rst explanation is that there is no immune eff ect of fi sh oil (and therefore no eff ect on infection rate) and that the benefi ts on length of stay relate to other eff ects (for example, on infl ammation [7] or gas exchange [3, 6] or both). Th e second explanation is that there is an immune eff ect of fi sh oil, resulting in shorter or less severe infections -but Abstract A meta-analysis of parenteral fi sh oil in 23 studies in intensive care unit (ICU) and non-ICU patients reported a reduced infection rate (signifi cant in ICU patients) and shorter lengths of ICU and hospital stays (both non-ICU and ICU patients). Parenteral fi sh oil reduced infl ammation and improved oxygenation index and liver function. The fi ndings of the meta-analysis are discussed in this report.
not in changes in the infection rate (that is, in the rate of becoming infected) -and this translates into a more rapid recovery. Although parenteral fi sh oil signifi cantly reduced length of hospital stay in non-ICU patients, many of these patients would not normally receive parenteral nutrition and certainly not for the typical period of 5 days used in the included studies. Furthermore, the lengths of hospital stay reported in these studies in non-ICU patients have little relevance to reallife clinical care of most patients undergoing uncom plicated elective abdomi nal surgery.
Pradelli and colleagues [1] present, for the fi rst time, a meta-analysis of laboratory outcomes. Of relevance to infl ammation, parenteral fi sh oil was found to significantly decrease interleukin-6 levels and to signifi cantly increase the ratio of omega-3 eicosapentaenoic acid (EPA)-derived leukotriene (LT) B 5 to omega-6 arachidonic acid (ARA)-derived LTB 4 with similar eff ects in ICU and non-ICU patients. Th e signifi cance of the latter fi nding is that LTB 4 is a potent chemoattractant for leukocytes and plays a role in amplifying lung infl ammation but that LTB 5 is much weaker in this regard [8] . Th us, this eff ect on fatty acid-derived mediators may be linked directly to the reported signifi cant improvement on oxygenation index in ICU patients, which in turn may be linked to shorter lengths of ICU and hospital stays. Th e production of the LTs is infl uenced by the relative availability of the substrate fatty acids, EPA and ARA. EPA is the major omega-3 fatty acid in fi sh oil, and when fi sh oil is administered parenterally, EPA appears in greater amounts in blood lipids [3, 6, 9] and in immune cells [10] . Liver enzymes were signifi cantly decreased by parenteral fi sh oil in both ICU and non-ICU patients, indicating an improvement in liver viability.
Overall, this meta-analysis confi rms the potential for improved cell and tissue function and clinical outcomes with parenteral fi sh oil in both ICU and non-ICU patients. Nevertheless, the individual studies considered have typically been small and often have not individually reported the improved outcomes seen with metaanalysis. Future research should focus on larger trials in patients in the ICU and should aim to consolidate the clinical fi ndings and to establish the causal chain of events from increased omega-3 fatty acid status through to improved clinical outcome and the optimal dose of fi sh oil required to exert the benefi ts seen.
Abbreviations ARA, arachidonic acid; EPA, eicosapentaenoic acid; ICU, intensive care unit; LP, leukotriene.
